bioAffinity Technologies, Inc. (BIAF)
1.73
+0.16
(+10.19%)
USD |
NASDAQ |
Dec 04, 16:00
1.73
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 7.783M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -95.24% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.188 |
| Price to Book Value | 0.8743 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0765 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX. |
| URL | http://www.bioaffinitytech.com |
| Investor Relations URL | https://ir.bioaffinitytech.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX. |
| URL | http://www.bioaffinitytech.com |
| Investor Relations URL | https://ir.bioaffinitytech.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |